Most Popular
June 19, 2024 | Wednesday
DNA Health & Wellness set to expand into Abu Dhabi
DNA Health & Wellness, the MENA region's first and largest health optimisation and longevity clinic group, is set to open its new clinic in Abu Dhabi in the third quarter of 2024. The new state-of-the-art facility will span over 10,000 sq. ft and offer a comprehensive range of health optimisation and longevity treatments, incorporating the latest in preventative health and precision medicine tailored to meet the unique and personalised needs of each client. Located in Central Abu Dhabi, the expansion marks a significant milestone in DNA Health & Wellness' mission to provide cutting-edge health services across the UAE. Offering the same comprehensive array of treatments as its Dubai clinics, DNA Health & Wellness Abu Dhabi will incorporate innovative technology and focus on four key disciplines: Prevention – proactive approach to health designed to detect and prevent health issues and diseases before they arise with the use of detailed blood testing, advanced diagnostic imaging and AI based reporting software; Optimisation – precision medicine to target and optimise health using the latest therapies such as peptides, hormonal therapy, exosomes, NAD+, stem cells, and disease reversal programmes; Rejuvenation – advanced aesthetic treatments using regenerative medicine such as pure exosomes and stem cells; and Longevity – in-depth longevity health screening and biological aging analysis combined with stem cells and DNA repair to help enhance health span and lifespan.
June 12, 2024 | Wednesday
Penn Medicine to expand collaboration on translational research in Abu Dhabi
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector, has signed a second Memorandum of Understanding (MoU) with the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine), US to expand partnership in education, research and innovation programmes. Both parties will further collaborate on translational research ecosystem development, as well as launch innovative collaborative research involving "second labs" that leverage and build capabilities in Abu Dhabi and at Penn Medicine in Philadelphia, Pennsylvania, US in leading-edge areas of science. The MoU has been signed by Dr Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at DoH and Mick Merritt, Chief Operating Officer and Lead for Global Clinical Programmes, at Perelman School of Medicine at Penn Medicine. Through this MoU, DoH and Penn Medicine seek to design and develop a translational medicine ecosystem based on Penn's Institute for Translational Medicine and Therapeutics (ITMAT). In addition, the MoU seeks to explore the potential of launching two multi-year collaborative research programmes. One focuses on the expanded application of artificial intelligence to identify new potential antibiotics. The other focuses on longitudinal follow-up and genetic analysis of people with Alzheimer's in Abu Dhabi that will facilitate cross-population comparative analysis and unique attributes that ultimately enable global prevention and early diagnosis. With the aim of bridging the gap between preliminary research and practical applications in medical practices, translational research seeks to translate research discoveries from laboratory findings and clinical studies into practical applications to improve human health. This collaboration will potentiate the development of a translational medicine and therapeutics ecosystem to further enable capacity development and the creation of novel discoveries and treatments in Abu Dhabi. This will involve the development of research training and educational programmes for healthcare professionals to upskill the workforce in various healthcare domains including medical science, biomedical research and health technology.
June 11, 2024 | Tuesday
Myriad Genetics collaborates with GSK to improve access to HRD testing in 9 countries
US-based Myriad Genetics, Inc., a leader in genetic testing and precision medicine, has announced a collaboration with British pharmaceutical firm GlaxoSmithKline (GSK) aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing programme leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad’s MyChoice Tests) is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudia Arabia, Singapore, and United Arab Emirates. HRD testing is an important predictive and prognostic biomarker for patients who have ovarian cancer. Myriad’s MyChoice Tests determine HRD status in women with ovarian cancer. Clinicians can order this test through their local pathology labs and samples are sent to Myriad Genetics. This collaboration delivers on both companies’ shared commitment to improve care for patients with advanced ovarian cancer by facilitating access to genetic testing and demonstrates a mutual dedication to meeting an unmet need for patients who otherwise may not have access to testing. “Our collaboration with GSK is an important step forward in providing critical genetic insights that can help clinicians guide more personalized ovarian cancer treatment decisions,” said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics. “In the pursuit of advancing healthcare equity, Myriad is committed to extending the reach of our diagnostic solutions, like Myriad’s MyChoice Tests into additional markets to support more targeted patient care based on their genomic profile.”
June 10, 2024 | Monday
Abu Dhabi strengthens position as global pharma and life sciences distribution hub
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and Abu Dhabi Investment Office (ADIO), Etihad Airways and AD Ports Group have signed a landmark Memorandum of Understanding (MoU) to strengthen Abu Dhabi's position as a global pharmaceutical and life sciences distribution hub, leveraging its strategic location, lucrative investment opportunities and advanced logistics capabilities. In the presence of Mansoor Ibrahim Al Mansouri, Chairman of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr Asma Ibrahim Al Mannaei Executive Director of the Research and Innovation Centre at DoH, Khalifa Al Mahmoud, Acting Director of Investor Attraction at Abu Dhabi Investment Office (ADIO), Stanislas Brun, Vice President of Etihad Cargo, and Mansoor Al Marar, Vice President, Industrial Business Development at KEZAD Group, a subsidiary of AD Ports Group. In line with the Abu Dhabi Economic Vision 2030, the MoU is a pivotal step in Abu Dhabi's ongoing efforts to become a leading healthcare destination in the global healthcare landscape. The strategic partnership aims to create attractive value propositions for pharmaceutical, biotechnology, and medical technology companies to establish their operations in Abu Dhabi. By capitalising on DoH's world-class regulatory framework, ADIO's attractive investment platform, Etihad Cargo's expertise in air freight, and AD Port's robust logistics infrastructure, the collaboration is set to position Abu Dhabi as a global healthcare and life-science distribution hub. As part of the agreement, the entities will work together to ensure timely access to innovative healthcare products for patients across the region, enhancing Abu Dhabi's role in global pharmaceutical supply chains. Aligned with the Emirate's economic aspirations, the collaboration is expected to attract significant investment in healthcare and logistics, promoting sustainable economic growth and diversification within the healthcare and life sciences sectors. The MoU also includes plans to support local manufacturing and packaging of pharmaceutical and biotechnology products, in addition to local capability enhancement.
Most Read
June 07, 2024 | Friday
Novartis partners with Abu Dhabi govt to advance genomics research in oncology
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE, a global pharmaceutical company. Under the terms of the MoU, the entities will work together to advance solutions in multiple therapeutic areas. The two priority focus areas include advancing clinical genomics research for real-world evidence (RWE) and generating and disseminating evidence to support the understanding of radioligand therapy (RLT) for cancer patients. In the presence of Thierry Diagana, Head of Global Health and California Sites Head at Novartis Biomedical Research, the MoU was signed by Dr Asma Ibrahim Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Ibrahim Aqel, Head of Government Affairs and Value & Access – Gulf at Novartis. This collaboration will utilise Abu Dhabi's genomics expertise as well as its future-forward, agile regulatory framework research hub to collaborate on future clinical research and the generation of RWE. This will include the exploration of innovative solutions and genomics research in oncology, cardiovascular disease, and neuroscience. The two will also work together to generate and disseminate evidence to support the awareness and understanding of RLT, a form of precision nuclear medicine that may recognise and treat disease in patients with advanced cancers, with key stakeholders, including policymakers, healthcare professionals and patient organisations. Under the MoU, Novartis will also work with DoH to explore innovative solutions for local and regional health needs. This will include supporting the Emirati Genome Programme by collaborating to raise awareness of genetic and rare diseases for the benefit of patients in Abu Dhabi and the broader region. The final focus area is supporting the further improvement of the Health Technology Assessment through facilitated partnership and shared best practice.
June 04, 2024 | Tuesday
Abu Dhabi government collaborates with Pfizer to advance research in sickle cell disease
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding (MoU) with Pfizer Gulf FZ LLC, a global pharmaceutical company. The entities will work to enhance Abu Dhabi's position as leading global hub for healthcare, life science and innovation. Leveraging the Emirate's unique capabilities and future-forward data services as well as Pfizer's global capabilities, the parties seek to advance research through the generation and analysis of real-world data (RWD) initially focusing on Sickle Cell Disease (SCD) and expanding to other disease areas for the benefit of patients. In the presence of Mansoor Al Mansoori, Chairman of DoH, the MoU was signed by Dr Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH, and Serhat Yalcinkaya, Pfizer's Gulf Cluster Lead. They will work together to advance Abu Dhabi's RWD capabilities by promoting global knowledge exchange and education of scientific ideas. The agreement will focus on upskilling the local healthcare workforce on RWD by establishing a dynamic and sustainable partnership model promoting education and awareness on real-world evidence (RWE) generation, collection and analysis in order to address unmet patient needs. Dr Asma Ibrahim Al Mannaei, said "The collaboration between the DoH and Pfizer represents a significant step towards harnessing real-world data in the region and better understanding patient populations from the vast available data in Abu Dhabi. By partnering with Pfizer on real-world data, we aim to drive advancements in healthcare prediction, prevention, personalised treatment and access, not only benefiting healthcare professionals and patients in Abu Dhabi, but also contributing to the improvement of care for patients globally."
June 05, 2024 | Wednesday
Japan's Takeda Pharma to advance research in rare diseases and oncology in Abu Dhabi
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding (MoU) with Japan-headquartered Takeda Pharmaceuticals. In the presence of Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at DoH and Dr Ahmed Fayed – General Manager East Gulf & Levant Cluster, at Takeda. The partnership will boost clinical research, innovation and facilitate regional advisory boards with expert panels to further advance knowledge sharing, discuss challenges, and propose solutions that effectively addressing healthcare gaps. DoH and Takeda will develop regional treatment guidelines and consensus statements promoting evidence-based practices to improve patient outcomes. Alongside, generating comprehensive evidence on epidemiology, and tackling unmet medical needs related to rare diseases and oncology, addressing targeted proactive interventions, and elevating healthcare outcomes in the region. In line with Abu Dhabi’s healthcare aspirations, both parties will collaborate to seamlessly integrate innovative Patient Support Programmes (PSPs) into the Emirate’s healthcare ecosystem. These programmes, tailored to the specific needs of rare disease patients, will leverage Takeda’s global experience and best practices. By assessing the impact and effectiveness of these PSPs, the two entities will improve patient outcomes, adherence to treatment, and quality of life. The collaboration will witness the launch of joint public awareness campaigns aimed at educating the public on the importance of early diagnosis and recognising rare disease signs and symptoms. Additionally, partnerships between local healthcare providers in both countries will foster educational programmes for professionals, focusing on cutting-edge diagnostic tools and techniques.
June 06, 2024 | Thursday
Rare Disease Centre of Excellence to open in Emirate in collaboration with AstraZeneca
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding (MoU) with AstraZeneca to establish a world-class Rare Diseases Centre of Excellence (CoE) in Abu Dhabi. Leveraging Abu Dhabi's advanced healthcare infrastructure and AstraZeneca's global expertise and experience in rare diseases management, the two entities will spearhead innovation to improve the lives of people and communities impacted by rare diseases, regionally and globally. In the presence of Mansoor Ibrahim Al Mansoori, Chairman of DoH and Hicham Mirghani, GCC and Pakistan Corporate Affairs Director at AstraZeneca, the MoU was signed by Dr Asma Ibrahim Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Ghaleb Al Ahdab, Head of Government Affairs, GCC and Pakistan at AstraZeneca. Data suggests genetic and congenital disorders are more common in the Arab Gulf than in other industrialised countries, leading to a high socio-economic burden on patients, families and communities. This collaboration will help to address this burden by allowing the two entities to work together to establish a Rare Disease Centre of Excellence in the Emirate, serving as a hub for comprehensive diagnosis, treatment, follow-up, research education and patient care with a focus on haematology, neurology, and metabolic disorders. The two will work together to redefine diagnostic processes, implement state-of-the-art early detection processes and innovate for new technologies for comprehensive patient management across some of the most devastating and hard to manage rare diseases.
Events
JPM Week Biotech Showcase 2025
San Francisco, USA
PepTalk 2025
San Diego, USA
Fierce JPM Week 2025
San Francisco
Latest News
Webinar
